Effects of canagliflozin on the hepatic steatosis, adipose tissue and skeletal muscle in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease / non-alcoholic steatohepatitis

Trial Profile

Effects of canagliflozin on the hepatic steatosis, adipose tissue and skeletal muscle in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease / non-alcoholic steatohepatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Fatty liver
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2017 Status changed from recruiting to completed.
    • 07 Oct 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 02 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top